A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

BACKGROUND: We conducted an open-label, pilot phase II trial to evaluate the efficacy and safety of FOLFOXIRI plus cetuximab as first-line treatment of patients with metastatic colorectal cancer (mCRC). METHODS: Thirty patients with KRAS wild-type mCRC, <70 years and with performance status 0–1 w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Saridaki, Z, Androulakis, N, Vardakis, N, Vamvakas, L, Kabouraki, E, Kalbakis, K, Hatzidaki, D, Voutsina, A, Mavroudis, D, Georgoulias, V, Souglakos, J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2012
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3516691/
https://ncbi.nlm.nih.gov/pubmed/23169296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.509
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi